1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
June 4, 2014
- Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
June 4, 2014
- Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
June 3, 2014
- Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
- MTPC to Merge Its Subsidiary Benesis in October
June 3, 2014
- Astellas Seeks Approval of Cell-Culture Seasonal Flu Vaccine
June 2, 2014
- FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
June 2, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
June 2, 2014
- Suglat Secures Top Position in Anterio’s “Mind Share” Ranking in Both GP, HP Markets in April
June 2, 2014
- Astellas, MSD Report 133 ADRs at EPPV for Suglat between January and April
June 2, 2014
- Takeda, US Biotech Venture Agree to Develop, Commercialize Autoimmune Disease Treatment
May 30, 2014
- Europe Approves Takeda’s UC, CD Treatment Entyvio
May 30, 2014
- Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
- Bayer Seeks New VTE Indication for Xarelto in Japan
May 30, 2014
- Atypical Antipsychotic Drug Asenapine Significantly Improves Symptoms of Schizophrenia in PIII Trial; Meiji Seika Pharma
May 30, 2014
- Introduction of Joint Bidding System to Result in 100% Price Agreement Rate by September: Mr Takada of Qol
May 30, 2014
- Eisai Receives Positive Opinion from CHMP on Expanded Indication for Halaven for Second-Line Treatment of Advanced Breast Cancer
May 30, 2014
- Shire Japan to Independently Launch Orphan Drug around September
May 29, 2014
- NDA for Once-Yearly Zoledronic Acid Injection Expected in FY2015: Asahi Kasei Pres. Asano
May 29, 2014
- Daiichi Sankyo’s Antiplatelet Agent Efient Now Available in Japan
May 28, 2014
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…